Markets

Strength Seen in Conatus Pharmaceuticals (CNAT): Stock Soars 56.7% - Tale of the Tape

Conatus Pharmaceuticals Inc. ( CNAT ) was a big mover last session, as the company saw its shares rise nearly 57% on the day. The move came on solid volume with more than 6 million shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.34 to $6.24 in the past one-month time frame.

The company has seen two positive estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Conatus Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other better-ranked medical stocks worth considering include Cardica Inc. ( CRDC ), ICU Medical, Inc. ( ICUI ) and NeuroMetrix Inc. ( NURO ). All these stocks have a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CONATUS PHARMA (CNAT): Free Stock Analysis Report

CARDICA INC (CRDC): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

NEUROMETRIX INC (NURO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ICUI HSTO NURO

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More